140 related articles for article (PubMed ID: 2506477)
1. 1-Deamino-8-D-arginine vasopressin lowers protein C activity in uremics.
Aunsholt NA; Schmidt EB; Stoffersen E
Nephron; 1989; 53(1):6-8. PubMed ID: 2506477
[TBL] [Abstract][Full Text] [Related]
2. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia.
Mannucci PM; Remuzzi G; Pusineri F; Lombardi R; Valsecchi C; Mecca G; Zimmerman TS
N Engl J Med; 1983 Jan; 308(1):8-12. PubMed ID: 6401193
[TBL] [Abstract][Full Text] [Related]
3. DDAVP in uremia.
Vicente V; Alberca I; Macias JF; Lopez Borrasca A
Nephron; 1984; 36(2):145-6. PubMed ID: 6420716
[No Abstract] [Full Text] [Related]
4. Properties of the factor VIII after DDAVP (1-deamino-8-D-arginine vasopressin) infusion in normal subjects.
Takahashi H; Itoh M; Kobayashi I; Sakuragawa N; Shibata A
Tohoku J Exp Med; 1980 Oct; 132(2):133-40. PubMed ID: 6777902
[TBL] [Abstract][Full Text] [Related]
5. [Effect of 1-deamino-8-D-arginine vasopressin (DDAVP) on bleeding time in uremic patients].
Alarcón F; Mezzano D; Vial S; Pereira J
Rev Med Chil; 1985 Aug; 113(8):763-8. PubMed ID: 3938558
[No Abstract] [Full Text] [Related]
6. Effect of desmopressin (DDAVP) on protein C and protein C inhibitors in uremia.
Akpolat T; Ozdemir O; Arik N; Demirkan F; Sungur C; Ozcebe O; Dündar S; Yasavul U; Turgan C; Kirazli S
Nephron; 1993; 64(2):232-4. PubMed ID: 8321356
[TBL] [Abstract][Full Text] [Related]
7. DDAVP, cryoprecipitate, and highly 'purified' factor VIII concentrate in uremia.
Juhl A
Nephron; 1986; 43(4):305-6. PubMed ID: 3090461
[No Abstract] [Full Text] [Related]
8. Shortening of bleeding time after intranasal administration of 1-deamino-8-D-arginine vasopressin to patients with chronic uremia.
Rydzewski A; Rowiński M; Myśliwiec M
Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(6):823-30. PubMed ID: 2436997
[TBL] [Abstract][Full Text] [Related]
9. [Multimeric composition of factor VIII-related protein following DDAVP infusion in normal subjects and patients with hemophilia A and von Willebrand's disease].
Takase T; Nishino M; Yasui M; Shima M; Yoshikawa N; Fukui H
Nihon Ketsueki Gakkai Zasshi; 1985 Nov; 48(7):1571-8. PubMed ID: 3937410
[No Abstract] [Full Text] [Related]
10. Effect of DDAVP on plasma level of factor XII.
Nenci GG; Berrettini M; De Cunto M; Agnelli G
Br J Haematol; 1983 Jul; 54(3):489-92. PubMed ID: 6407513
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous injection of desmopressin (DDAVP): evaluation of a new, more concentrated preparation.
Köhler M; Hellstern P; Tarrach H; Bambauer R; Wenzel E; Jutzler GA
Haemostasis; 1989; 19(1):38-44. PubMed ID: 2493411
[TBL] [Abstract][Full Text] [Related]
12. Is the pro-adhesive activity of plasma von Willebrand factor counteracted by a physiological inhibitor of platelet adhesiveness?
Porta M; Cagliero E; Kohner EM
Clin Sci (Lond); 1982 Feb; 62(2):239-42. PubMed ID: 6797774
[TBL] [Abstract][Full Text] [Related]
13. Effect of 1-deamino-8-D-arginine vasopressin on the prolonged bleeding time in chronic renal failure.
Watson AJ; Keogh JA
Nephron; 1982; 32(1):49-52. PubMed ID: 6817151
[TBL] [Abstract][Full Text] [Related]
14. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.
Casonato A; Dannhauser D; Pontara E; Bertomoro A; Orazi B; Santarossa L; Zerbinati P; Girolami A
Blood Coagul Fibrinolysis; 1996 Jul; 7(5):549-53. PubMed ID: 8874865
[TBL] [Abstract][Full Text] [Related]
15. Uremic plasma after infusion of desmopressin (DDAVP) improves the interaction of normal platelets with vessel subendothelium.
Escolar G; Cases A; Monteagudo J; Garrido M; Lopez J; Ordinas A; Revert L; Castillo R
J Lab Clin Med; 1989 Jul; 114(1):36-42. PubMed ID: 2738447
[TBL] [Abstract][Full Text] [Related]
16. [Response to DDAVP in von Willebrand disease type II C].
Batllé Fonrodona J; López Fernández MF; Martín González R; Fernández Villamor A; López Borrasca A; Lasierra Cirujeda J
Sangre (Barc); 1985; 30(2):181-4. PubMed ID: 3925573
[No Abstract] [Full Text] [Related]
17. Study on mechanisms of a haemostatic effect of 1 deamino-8-D-arginine vasopressin (desmopressin) in uraemic patients.
Malyszko J; Pietraszek M; Buczko W; Mysliwiec M
Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(2):319-24. PubMed ID: 1697836
[TBL] [Abstract][Full Text] [Related]
18. Fibrinolytic activators and inhibitors in terminal renal insufficiency and in anephric patients.
Brommer EJ; Schicht I; Wijngaards G; Verheijen JH; Rijken DC
Thromb Haemost; 1984 Dec; 52(3):311-4. PubMed ID: 6085194
[TBL] [Abstract][Full Text] [Related]
19. Normal response of factor VIII and von Willebrand factor to 1-deamino-8D-arginine vasopressin in nephrogenic diabetes insipidus.
Brenner B; Seligsohn U; Hochberg Z
J Clin Endocrinol Metab; 1988 Jul; 67(1):191-3. PubMed ID: 3132483
[TBL] [Abstract][Full Text] [Related]
20. Intranasal deamino-8-D-arginine vasopressin shortens the bleeding time in uremia.
Shapiro MD; Kelleher SP
Am J Nephrol; 1984; 4(4):260-1. PubMed ID: 6332534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
